3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Arthritis, Rheumatoid
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Graft vs Host Disease
6
Leukemia
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Lymphoma, Follicular
4
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
3
Lymphoma
3
Psoriasis
2
Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Accelerated Phase
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Burkitt Lymphoma
2
Urinary Bladder Neoplasms
1
Stomatitis
1
Recurrence
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neutropenia
1
Mycosis Fungoides
1
Multiple Myeloma
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoproliferative Disorders
1
Interventions
Brentuximab Vedotin
2
Bexarotene
2
iratumumab
1
Vitamin B 12
1
Methotrexate
1
Folic Acid
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Primary Cutaneous Anaplastic Large Cell
×
Methotrexate
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts